Holmium-166 Scout (QuiremScout™) Has Shown Superior Predictive Value When Compared to Technetium-99m-macroaggregated Albumin During SIRT Work-up

Terumo Europe N.V. is proud to share our latest key publication regarding holmium-166 (QuiremSpheres™) Selective Internal Radiation Therapy (SIRT). On 9th August 2019, UMC Utrecht published its results from a recent study on the comparison of QuiremScout™ to technetium-99m-macroaggregated albumin (^99mTc-MAA) as a SIRT work-up which is used to select patients with liver cancer who will benefit from SIRT treatment.

The aim of this study was to analyze whether the intrahepatic distribution of QuiremScout™ has a better agreement with the QuiremSpheres™ distribution when compared with ^99mTc-MAA. It has been indicated in several scientific papers, the widely used Tech-99m-MAA has limited predictive value.

This study included 53 patients which had been included in either phase 1 and phase 2 Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies and showed QuiremScout™ to have a superior predictive value for intrahepatic distribution in comparison to ^99mTc-MAA.

"Previous studies already demonstrated that QuiremScout™ is safe¹ in this population and moreover a better predictor for lung shunting than to ^99mTc-MAA. As a result, QuiremScout™ allows for more accurate SIRT patient selection. Now, our study shows the potential of QuiremScout™ to also improve the efficacy of SIRT, by allowing a more accurate and truly personalized pre-treatment activity planning." says Maarten Smits MD PhD, first author of the article².

"This is an important next step towards unlocking the full potential of QuiremScout™." said Rijk de Jong, Medical Director of Quirem Medical. "Smits et al. publication further strengthens the evidence base of QuiremScout™, demonstrating superiority over ^99mTc-MAA in the evaluation of the subsequent treatment. We believe this will translate into enhanced efficacy and safety for the benefit of patients undergoing SIRT procedures."

"This is a very exciting milestone for QuiremScout™ and the next step in building the future for SIRT." added Peter Coenen, President of Interventional Systems Terumo EMEA. "This publication further validates the advantages of QuiremScout™ over ^99mTc-MAA during the SIRT work up, which we at Terumo believe is a vital step in advancing patient selection and optimizing dosimetry for better patient outcomes."

Results from this trial are published in the European Journal of Nuclear Medicine Molecular Imaging 2019. QuiremScout™ is the first SIRT work-up product that utilizes the same technology as the therapeutic microspheres, which aims to optimize patient selection and advance treatment planning when compared to using ^99mTc-MAA.

• 1

  Braat AJAT et al. Eur Radiol 2017

• 2

  Smits, et al. Eur. J. Nucl. Med. Mol. Imaging 2019

About Quirem Medical

At Quirem Medical, we develop and commercialize the next-generation Selective Internal Radiation Therapy (SIRT) microspheres based on the radioisotope Holmium-166. We believe the treatment outcome of unresectable liver cancer with SIRT can be optimized with Holmium-166 microspheres, which can be visualized and quantified to improve SIRT patient selection, treatment planning and treatment verification. Our innovative Holmium-166 platform technology provides physicians a complete CE-marked SIRT solution including QuiremScout™, QuiremSpheres™ and the supporting dosimetry software Q-Suite™.